Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNF inhibitor dose reduction and withdrawal strategies in psoriatic arthritis and axial spondyloarthritis
2018-003432-72Phase 4Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Sep 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab, certolizumab pegol, etanercept, golimumab and infliximab in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) (2 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Sustained low disease activity. Started Sep 2018; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2018-003432-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003432-72.